- Accueil >
- Publications >
- Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
Auteurs
Rayan Dakroub, Solène Huard, Yara Hajj-Younes, Samyuktha Suresh, Bassam Badran, Hussein Fayyad-Kazan, Thierry Dubois
